Pharmaceutical

Agilent agrees to acquire BIOVECTRA for $925m

Agilent Technologies has announced a definitive agreement for the acquisition of Canadian CDMO BIOVECTRA in a deal worth $925m.

Jul 24, 2024 - 04:00
Agilent agrees to acquire BIOVECTRA for $925m
Agilent Technologies has announced a definitive agreement for the acquisition of Canadian CDMO BIOVECTRA in a deal worth $925m.
Read the original article

Tags:

Previous Article

Podcast #5: Doing Digital Deals in Life Sciences | Deal Structure, Terms, and Se...

Next Article

FDA approves Samsung Bioepis’ EPYSQLI as Soliris biosimilar

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Novo Holdings acquires biopharma company Paratek for $462m

Novo Holdings acquires biopharma company Paratek for $462m

Sep 23, 2023

STAT+: It’s time for the FDA to halt Cassava Sciences’ Alzheimer’s clinical trials

STAT+: It’s time for the FDA to halt Cassava Sciences’ ...

Oct 18, 2023

STAT+: In the U.S., scientists see barriers to the development of CAR-T cell therapies. In Spain, a hospital brews its own

STAT+: In the U.S., scientists see barriers to the deve...

Dec 19, 2023